The New Treatment Grant funds advanced, innovative research projects in Australia aimed at accelerating the clinical development of new pancreatic cancer treatments, supporting the translation of promising therapies, scaling existing work, and contributing to the goal of tripling survival by 2030.

The New Treatment Grant will provide funding to Australian researchers to:

• Carry out developed projects that will significantly accelerate treatments to a clinical stage for pancreatic cancer patients
• Contribute to advancing the translation of research from the lab to clinical studies or practice; accelerate the translation of promising therapies to clinical application
• Contribute to innovative projects that require resources to advance critical milestones
• Extend previous or existing work for a new treatment, scaling up existing research
• Grow capacity in pancreatic cancer research in Australia
• Improve survival from pancreatic cancer in line with our mission to triple survival by 2030

These projects should focus on more developed solutions that have the potential to move to clinical studies and make a significant impact on advancing the therapeutic field.

Criteria for funding

• Projects which are well developed, part of a larger program of work may be suited to this scheme
• Pilot or preliminary data should be developed and detailed as relevant to the application
• Where applications have multiple AI's, the role of each co-investigator must be outlined and justified
• Only one application per institution may be submitted for each scheme
• International collaborations are encouraged if the PI is located in Australia

Pankind will only fund projects where:

1. Only one application per institution may be submitted for each scheme.
2. The administering institution agrees to the terms and conditions of funding as outlined on this page and in Pankind's Research Funding Agreement. Please note amendments to the agreement terms are generally not accepted, so please ensure the agreement is reviewed prior to submitting your application.
3. The application has been submitted using Pankind's Grant Application Form (will be available early in 2025).
4. The grant applicant (Principal Investigator) resides in Australia.
5. The grant applicant's administering institution is an Australian organisation.
6. The applicant is the Principal Investigator on no more than one application across all grant categories.
7. The applicant and research team members are each funded at a maximum of 1 full-time equivalent.
8. If, at the time of application you currently hold a Pankind grant as a Principal Investigator, your grant will finish within the current calendar year. Please note we reserve the right to alter or withdraw our offer of award if you do not fulfil the requirements of your currently held grant.
9. Biotechnology, pharmaceutical or other relevant companies may apply for funding, however, if successful Pankind may vary the terms of funding.
10. Grantees will be required to present the results of their research at a future event or special session to be held by Pankind.

• Phone: (02) 7207 6970
• Email: info@pankind.org.au